Vincent Javinal
Overview
Explore the profile of Vincent Javinal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
966
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sriraman S, Davies C, Gill H, Kiefer J, Yin J, Ogasawara A, et al.
Eur J Nucl Med Mol Imaging
. 2022 Nov;
50(3):679-691.
PMID: 36346438
Purpose: Cancer immunotherapies (CITs) have revolutionized the treatment of certain cancers, but many patients fail to respond or relapse from current therapies, prompting the need for new CIT agents. CD8...
2.
Barreira da Silva R, Leitao R, Pechuan-Jorge X, Werneke S, Oeh J, Javinal V, et al.
Nat Immunol
. 2022 Mar;
23(4):568-580.
PMID: 35314846
Tumor-associated macrophages are composed of distinct populations arising from monocytes or tissue macrophages, with a poorly understood link to disease pathogenesis. Here, we demonstrate that mouse monocyte migration was supported...
3.
Vormehr M, Lehar S, Kranz L, Tahtinen S, Oei Y, Javinal V, et al.
Oncoimmunology
. 2020 Sep;
9(1):1758004.
PMID: 32923115
Glucocorticosteroids (GCS) have an established role in oncology and are administered to cancer patients in routine clinical care and in drug development trials as co-medication. Given their strong immune-suppressive activity,...
4.
de Almeida P, Mak J, Hernandez G, Jesudason R, Herault A, Javinal V, et al.
Cancer Immunol Res
. 2020 Apr;
8(6):806-818.
PMID: 32238381
Antiangiogenic therapies that target the VEGF pathway have been used clinically to combat cancer for over a decade. Beyond having a direct impact on blood vessel development and tumor perfusion,...
5.
Riegler J, Gill H, Ogasawara A, Hedehus M, Javinal V, Oeh J, et al.
Neoplasia
. 2019 Sep;
21(10):1036-1050.
PMID: 31521051
Cancer immunotherapies have demonstrated durable responses in a range of different cancers. However, only a subset of patients responds to these therapies. We set out to test if non-invasive imaging...
6.
Du X, De Almeida P, Manieri N, de Almeida Nagata D, Wu T, Bowles K, et al.
Proc Natl Acad Sci U S A
. 2018 Dec;
115(50):E11731-E11740.
PMID: 30504141
Natural killer (NK) cell recognition of tumor cells is mediated through activating receptors such as CD226, with suppression of effector functions often controlled by negative regulatory transcription factors such as...
7.
Riegler J, Labyed Y, Rosenzweig S, Javinal V, Castiglioni A, Dominguez C, et al.
Clin Cancer Res
. 2018 May;
24(18):4455-4467.
PMID: 29798909
The tumor microenvironment presents with altered extracellular matrix (ECM) and stroma composition, which may affect treatment efficacy and contribute to tissue stiffness. Ultrasound (US) elastography can visualize and quantify tissue...
8.
Lau J, Cheung J, Navarro A, Lianoglou S, Haley B, Totpal K, et al.
Nat Commun
. 2017 Feb;
8:14572.
PMID: 28220772
Expression of PD-L1, the ligand for T-cell inhibitory receptor PD-1, is one key immunosuppressive mechanism by which cancer avoids eradication by the immune system. Therapeutic use of blocking antibodies to...
9.
Johnston R, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, et al.
Cancer Cell
. 2014 Dec;
26(6):923-937.
PMID: 25465800
Tumors constitute highly suppressive microenvironments in which infiltrating T cells are "exhausted" by inhibitory receptors such as PD-1. Here we identify TIGIT as a coinhibitory receptor that critically limits antitumor...